Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Recursion Pharmaceuticals Inc Cl A
(NQ:
RXRX
)
9.416
+0.256 (+2.80%)
Streaming Delayed Price
Updated: 11:11 AM EDT, May 28, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Recursion Pharmaceuticals Inc Cl A
< Previous
1
2
Next >
Recursion Appoints Robert Hershberg M.D., Ph.D, as New Chair of the Board
May 24, 2024
Dr. Hershberg is a current board member with over 25 years of experience as a physician, scientist, and entrepreneur
From
Recursion Pharmaceuticals
Via
GlobeNewswire
The Next Drug You Take May be Designed By A.I.
May 14, 2024
Three stocks could give investors a better way to tap into A.I.'s future potential inside drug development, an industry that is set to grow at 29.6% until 2030
Via
MarketBeat
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Recursion Provides Business Updates and Reports First Quarter 2024 Financial Results
May 09, 2024
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Recursion to Report First Quarter 2024 Business Updates and Financial Results on May 9
May 02, 2024
Company to host public L(earnings) Call on May 9 at 5:00 pm ET
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Recursion Announces Completion of NVIDIA-Powered BioHive-2, the Largest Supercomputer in Pharmaceutical Industry
May 13, 2024
BioHive-2, an NVIDIA DGX SuperPOD with NVIDIA DGX H100 systems, ranked #35 in the TOP500 list of the most powerful supercomputers in the world across all industries as of May 2024.
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Recursion to Participate in Upcoming Investor Conferences
May 01, 2024
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Altitude Lab Secures Small Business Administration Growth Fund Accelerator Grant to Launch Horizon, a Commercialization Partnering Program
April 30, 2024
The grant designates Altitude Lab as a top acceleration program for biotechnology startups
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial Officer
April 16, 2024
Dr. Khan, formerly the Chief Data Science Officer and Global Head of Strategy and Portfolio, Innovative Medicine R&D at Johnson & Johnson (J&J), will also join Recursion’s Board of Directors
From
Recursion Pharmaceuticals, Inc.
Via
GlobeNewswire
Recursion to Participate in Upcoming Investor Conference
April 02, 2024
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Recursion Publishes Annual Environmental, Social and Governance Report
March 26, 2024
Provides progress updates in support of long-term commitments focused on reducing greenhouse gas emissions, improving workforce diversity and accelerating community impact.
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Recursion Announces Plans to Open New Office in London
March 11, 2024
Appoints Michael Bronstein as Scientific Advisor and launches recruiting effort to fill the first 20 open roles across technology and biology, establishing a hub for world-class TechBio talent in the...
From
Recursion Pharmaceuticals, Inc.
Via
GlobeNewswire
Recursion Hosts Second Annual Rare Disease Day Events for Utah’s Rare Disease Community
March 01, 2024
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Recursion to Participate in Upcoming Investor Conferences
March 01, 2024
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2023 Financial Results
February 27, 2024
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Recursion to Host Public L(earnings) Call on February 27
February 20, 2024
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Altitude Lab Startups Raise Over $120M in Capital
January 24, 2024
Launches Fellowship Grant Opportunity for Early Career Entrepreneurs
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Recursion Unveils LOWE Drug Discovery Software at the J.P. Morgan Healthcare Conference
January 08, 2024
Recursion and NVIDIA will host an invite-only event on Wednesday, January 10, where Recursion will provide live demonstrations of LOWE, its new LLM-based software that can perform complex drug...
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Recursion Adds New Chemical Entity Targeting Fibrotic Diseases to Late Discovery Pipeline
January 04, 2024
Potential First-in-Class Novel Molecule with Novel Target In-Licensed from Collaboration with Bayer
From
Recursion Pharmaceuticals, Inc.
Via
GlobeNewswire
Recursion to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8
January 03, 2024
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Recursion and Enamine to Generate and Design Enriched Compound Libraries for Global Drug Discovery Industry
December 20, 2023
Screening libraries will leverage Recursion's MatchMaker tool to identify compounds across Enamine REAL Space predicted to bind to high-value targets.
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Unlocking AI investment opportunities in healthcare
November 16, 2023
AI is revolutionizing healthcare by improving diagnosis and accelerating drug discovery. An often-overlooked sector with a wealth of AI opportunities.
Via
MarketBeat
Topics
Artificial Intelligence
ETFs
Exposures
Artificial Intelligence
Bayer and Recursion Focus Research Collaboration on Oncology
November 09, 2023
Digitally enabled drug discovery for oncology has the potential to accelerate the delivery of new cancer therapies to patients. Drug discovery research collaboration may initiate up to seven oncology...
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Recursion Announces Data Collaboration Deal with Tempus, Top 50 Supercomputer Ambition Powered by NVIDIA, and Updated Focus of Collaboration with Bayer to Precision Oncology
November 09, 2023
With additional patient-centric data, compute power, and an exciting new focus for its Bayer collaboration, the company is accelerating the shift of biotech to techbio
From
Recursion Pharmaceuticals, Inc.
Via
GlobeNewswire
Recursion Provides Business Updates and Reports Third Quarter 2023 Financial Results
November 09, 2023
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Recursion to Participate in Upcoming Investor Conference
November 02, 2023
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Recursion to Participate in Upcoming Investor Conferences
September 05, 2023
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Recursion Announces Completion of Phase 1 Study for REC-3964 for Clostridioides Difficile Infection
September 05, 2023
REC-3964 has been well tolerated in healthy volunteers with no reported serious adverse events. Recursion to explore initiating a Phase 2 proof-of-concept study in patients with recurrent...
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Recursion Bridges the Protein and Chemical Space with Massive Protein-Ligand Interaction Predictions Spanning 36 Billion Compounds
August 08, 2023
Recursion has predicted the protein target(s) for approximately 36 billion chemical compounds in the Enamine REAL Space, reported to be the world’s largest searchable chemical library. These advances...
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Recursion Provides Business Updates and Reports Second Quarter 2023 Financial Results
August 08, 2023
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Recursion to Participate in Upcoming Investor Conference
August 01, 2023
From
Recursion Pharmaceuticals
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.